GlassScriptPhysician profile
Matthew Doepking
NPI 1750430906
$3,227.84
in general payments reported to CMS, 2019-2025
14 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $321 · 2023: $1,082 · 2024: $652 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,838 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,837.62 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,506.49 | 2023-2025 | Botox, Skyrizi |
| Journey Medical Corporation | $597.15 | 2023-2025 | Emrosi |
| Allergan, INC. | $259.04 | 2022 | |
| Genzyme Corporation | $232.84 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $199.06 | 2023-2024 | Ilumya |
| Galderma Laboratories, L.P. | $97.99 | 2023-2024 | |
| Incyte Corporation | $81.41 | 2023-2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $78.73 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $43.25 | 2023 | Olumiant, Taltz |
| Amgen INC. | $33.78 | 2023 | Otezla |
| Revance Therapeutics, INC. | $25.69 | 2024 | Daxxify |
| Merz North America, INC. | $25.01 | 2023 | Xeomin |
| Lnhc, INC | $24.90 | 2025 | Zelsuvmi |
| Solta Medical, A Division of Bausch Health US, LLC | $22.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Doepking listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.